ArticleTherapeutic advances in medical oncology2023

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.

Paula Jimenez-Fonseca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.